186 related articles for article (PubMed ID: 37381590)
1. The gut microbiome affects response of treatments in HER2-negative advanced gastric cancer.
Han Z; Cheng S; Dai D; Kou Y; Zhang X; Li F; Yin X; Ji J; Zhang Z; Wang X; Zhu N; Zhang Q; Tan Y; Guo X; Shen L; Peng Z
Clin Transl Med; 2023 Jul; 13(7):e1312. PubMed ID: 37381590
[TBL] [Abstract][Full Text] [Related]
2. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.
Mao J; Wang D; Long J; Yang X; Lin J; Song Y; Xie F; Xun Z; Wang Y; Wang Y; Li Y; Sun H; Xue J; Song Y; Zuo B; Zhang J; Bian J; Zhang T; Yang X; Zhang L; Sang X; Zhao H
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34873013
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of PD-1/PD-L1 inhibitor combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis.
Liu BW; Shang QX; Yang YS; Chen LQ
Front Oncol; 2023; 13():1077675. PubMed ID: 37114136
[TBL] [Abstract][Full Text] [Related]
4. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
Moehler M; Högner A; Wagner AD; Obermannova R; Alsina M; Thuss-Patience P; van Laarhoven H; Smyth E
Eur J Cancer; 2022 Nov; 176():13-29. PubMed ID: 36183651
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in Gastric Cancer.
Högner A; Moehler M
Curr Oncol; 2022 Mar; 29(3):1559-1574. PubMed ID: 35323331
[TBL] [Abstract][Full Text] [Related]
6. Combination treatment with anti-HER2 therapeutic antibody RC48, PD-1 inhibitor, radiotherapy, and granulocyte macrophage-colony stimulating factor (GM-CSF) in patient with metastatic gastric cancer: a case report.
Liu Z; Wang F; Zhang Y; Lu J; Yang Y
Front Immunol; 2024; 15():1321946. PubMed ID: 38361930
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK; Chen LT; Ryu MH; Oh DY; Oh SC; Chung HC; Lee KW; Omori T; Shitara K; Sakuramoto S; Chung IJ; Yamaguchi K; Kato K; Sym SJ; Kadowaki S; Tsuji K; Chen JS; Bai LY; Oh SY; Choda Y; Yasui H; Takeuchi K; Hirashima Y; Hagihara S; Boku N
Lancet Oncol; 2022 Feb; 23(2):234-247. PubMed ID: 35030335
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma.
Porth I; Hirsch D; Ceribas Y; Weidner P; Weichert W; Götze TO; Perner S; Luley K; Heyer CM; de la Torre C; Hofheinz RD; Lorenzen S; Gaiser T
Eur J Cancer; 2023 Apr; 183():119-130. PubMed ID: 36848831
[TBL] [Abstract][Full Text] [Related]
9. Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A.
Catenacci DVT; Kang YK; Yoon HH; Shim BY; Kim ST; Oh DY; Spira AI; Ulahannan SV; Avery EJ; Boland PM; Chao J; Chung HC; Gardner F; Klempner SJ; Lee KW; Oh SC; Peguero J; Sonbol MB; Shen L; Moehler M; Sun J; Li D; Rosales MK; Park H
ESMO Open; 2022 Oct; 7(5):100563. PubMed ID: 36029651
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
11. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
12. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.
Zeng Z; Yang B; Liao Z
Future Oncol; 2021 Apr; 17(12):1553-1569. PubMed ID: 33397136
[TBL] [Abstract][Full Text] [Related]
13. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
Lv JB; Yin YP; Zhang P; Cai M; Chen JH; Li W; Li G; Wang Z; Wang GB; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):84-92. PubMed ID: 36650004
[No Abstract] [Full Text] [Related]
14. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
Shah MA; Kennedy EB; Alarcon-Rozas AE; Alcindor T; Bartley AN; Malowany AB; Bhadkamkar NA; Deighton DC; Janjigian Y; Karippot A; Khan U; King DA; Klute K; Lacy J; Lee JJ; Mehta R; Mukherjee S; Nagarajan A; Park H; Saeed A; Semrad TJ; Shitara K; Smyth E; Uboha NV; Vincelli M; Wainberg Z; Rajdev L
J Clin Oncol; 2023 Mar; 41(7):1470-1491. PubMed ID: 36603169
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of anti-PD-1/PD-L1 agents vs chemotherapy in patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis.
Wang BC; Zhang ZJ; Fu C; Wang C
Medicine (Baltimore); 2019 Nov; 98(47):e18054. PubMed ID: 31764833
[TBL] [Abstract][Full Text] [Related]
17. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
Fashoyin-Aje L; Donoghue M; Chen H; He K; Veeraraghavan J; Goldberg KB; Keegan P; McKee AE; Pazdur R
Oncologist; 2019 Jan; 24(1):103-109. PubMed ID: 30120163
[TBL] [Abstract][Full Text] [Related]
18. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
19. The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer.
Peng Z; Cheng S; Kou Y; Wang Z; Jin R; Hu H; Zhang X; Gong JF; Li J; Lu M; Wang X; Zhou J; Lu Z; Zhang Q; Tzeng DTW; Bi D; Tan Y; Shen L
Cancer Immunol Res; 2020 Oct; 8(10):1251-1261. PubMed ID: 32855157
[TBL] [Abstract][Full Text] [Related]
20. The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction.
Valkema MJ; Mostert B; Lagarde SM; Wijnhoven BPL; van Lanschot JJB
Updates Surg; 2023 Feb; 75(2):313-323. PubMed ID: 35836094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
